Also known as: Medipost, MEDIPOST, MEDIPOST Inc.
MEDIPOST treated the first U.S. participant in a Phase III trial of its umbilical cord blood-derived MSC therapy for knee osteoarthritis. The FDA agreed the single pivotal study, supported by prior trials in South Korea and Japan, can support a planned BLA filing.
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
MEDIPOST has submitted an investigational new drug amendment to the FDA to initiate a Phase III trial of its umbilical cord blood-derived mesenchymal stem cell therapy for knee osteoarthritis, with patient enrollment expected in the first half of 2026.
